471 patents currently held
91 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
47
Ending by 2030
Jan 2027
Next term end
347
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2038 · High confidence
Also notable
Ends May 2027 · Medium confidence
Also notable
Ends Sep 2030 · High confidence
Also notable
Ends Jan 2030 · High confidence
Also notable
Ends Feb 2027 · High confidence
Also notable
Ends Nov 2028 · High confidence
Also notable
Ends Jan 2027 · High confidence
Also notable
Ends Jun 2033 · High confidence
Cardiac Valve Leaflet Enhancer Devices and Systems
US 11,571,305
Cited by 35 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2038.
Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle
US 10,905,586
Cited by 18 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions
US 8,822,462
Cited by 45 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Human ANTI-PD-1 Antibodies and Uses Therefor
US 9,102,727
Cited by 103 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Catheter for Modified Perfusion
US 7,686,781
Cited by 97 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Conduit Device and System for Implanting a Conduit Device in a Tissue Wall
US 7,846,123
Cited by 74 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Virus-like particles, methods of preparation, and immunogenic compositions
US 9,045,727
Cited by 71 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2027.
ANTI-CD40 Antibodies and Methods of Administering Thereof
US 9,987,356
Cited by 31 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Formerly held, still cited
Notable
Ends Sep 2029 · High confidence
The most cited patent in this portfolio, cited by 314 later US patents, top 1% of utility patents granted in 2013 in our data. Protection runs to 2029.
now held by Dana-Farber Cancer Institute, Inc.
Also notable
Ends Feb 2029 · High confidence
Cited by 258 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
now held by Georgia Tech Research Corporation
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 7 fees due Dec 6 to 23, 2026 · next Dec 6
- 6 fees due Jan 2 to 28, 2027 · next Jan 2
- 16 fees due Feb 1 to 28, 2027 · next Feb 1
- 6 fees due Mar 5 to 24, 2027 · next Mar 5
- 8 fees due Apr 3 to 30, 2027 · next Apr 3
- 8 fees due May 5 to 28, 2027 · next May 5
- 9 fees due Jun 8 to 26, 2027 · next Jun 8
- 16 fees due Jul 2 to 30, 2027 · next Jul 2
- 5 fees due Aug 11 to 27, 2027 · next Aug 11
- 3 fees due Sep 24 to 29, 2027 · next Sep 24
- 11 fees due Oct 14 to 30, 2027 · next Oct 14
- 5 fees due Nov 7 to 19, 2027 · next Nov 7
Recent changes
- Nov 17Assignment recorded on 1 record: Painter, George R. and 3 others to Emory University Recorded Nov 17, 2026, executed Aug 7, 2015. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76789, frame 530.
- Oct 29Assignment recorded on 2 records: Suresh, Kirthana Sreerangathama to Emory University Recorded Oct 29, 2026, executed Jun 6, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76563, frame 634.
- 18 of the patents on this record were granted since Aug 22, 2026
- 8 terms have ended since Aug 22, 2026
- Oct 18 US 9,457,080 Methods and Compositions for the Treatment of Persistent Infections and Cancer by Inhibiting the Programmed Cell Death 1 (PD-1) Pathway · term ended
- Oct 18 US 10,370,446 Methods and Compositions for the Treatment of Persistent Infections and Cancer by Inhibiting the Programmed Cell Death 1 (PD-1) Pathway · term ended
- Oct 9 US 10,093,609 TAK1 Kinase Inhibitors, Compositions, and Uses Related Thereto · lapsed on the fee record
- Sep 30 US 8,846,624 Modified Protein Polymers · lapsed on the fee record
- Sep 23 US 8,841,276 Fulvene and Fulvalene Analogs and Their Use in Treating Cancers · lapsed on the fee record
- Sep 2 US 8,822,367 Polyoxometalate Water Oxidation Catalysts and Methods of Use Thereof · lapsed on the fee record
- Sep 2 US 8,821,135 Devices and Systems for Medical Fluid Treatment · lapsed on the fee record
- Aug 26 US 8,815,829 3'-Azido Purine Nucleotide Prodrugs for Treatment of Viral Infections · lapsed on the fee record
What they patent
The largest of its 347 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,045,727 | Virus-like particles, methods of preparation, and immunogenic compositions In force · High confidence | In force | High confidence | |
| US 7,652,033 | HIF-1 Inhibitors In force · High confidence | In force | High confidence | |
| US 7,686,781 | Catheter for Modified Perfusion In force · High confidence | In force | High confidence | |
| US 10,905,586 | Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle In force · Medium confidence | In force | Medium confidence | |
| US D685,387 | Graphical User Interface for a Display Screen or a Portion Thereof In force · High confidence | In force | High confidence | |
| US 7,550,299 | Method for Predicting Onset/Risk of Atrial Fibrillation (AF) held by U.S. Department of Veterans Affairs and Emory University In force · High confidence | In force | High confidence | |
| US 10,787,641 | Therapeutic Use of CD31 Expressing Cells In force · High confidence | In force | High confidence | |
| US 7,824,672 | Method for Coating Living Cells In force · High confidence | In force | High confidence | |
| US 7,691,289 | Compositions, Materials Incorporating the Compositions, and Methods of Using the Compositions and Materials In force · High confidence | In force | High confidence | |
| US D696,094 | Accessory Clamp In force · High confidence | In force | High confidence |
Also on record, not counted in the 471: 91 patents in force now held by others · 176 patents ended · 282 applications pending · 434 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.